Skip to main content

Security report for keytruda.com

Merck · Healthcare · United States

Medium risk. 3 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

73/100

Risk levelMedium

0–100, higher is better. How it is calculated

The website www.keytruda.com serves as the official patient-facing platform for KEYTRUDA®, an immunotherapy drug developed by Merck & Co., Inc. It provides comprehensive information about the drug's indications, safety information, side effects, and patient resources. The site targets patients in the United States and its territories, offering educational content and support to help patients understand treatment options. The site is well-branded and professionally designed, reflecting Merck's position as a leading pharmaceutical company in oncology treatments. Technically, the site leverages modern web technologies including React and Next.js, with embedded video content via Brightcove and analytics through Google Tag Manager. The site is mobile-optimized and accessible, with good SEO practices implemented. Security posture is strong with HTTPS enforced and appropriate security headers present, though explicit security and incident response policies are not publicly detailed. WHOIS data is unavailable, likely due to privacy protection, but the site's content and branding strongly support its legitimacy. Overall, the site presents a trustworthy, professional resource for patients seeking information about KEYTRUDA treatment.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • High

      No SPF record found

      SPF helps prevent email spoofing

      What to do: Add SPF record: "v=spf1 include:_spf.yourmailprovider.com ~all"

Need hands-on remediation? Email guard@offseq.com

Keep watching keytruda.com

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
90
Security headers
45
Email security
50
DNS health
85
Network security
100
GDPR outside view
68
Average
73

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

KEYTRUDA.com is positioned as a critical digital asset for Merck's oncology portfolio, focusing on patient education and support. The business model centers on pharmaceutical marketing and patient engagement, providing detailed drug information, safety guidelines, and financial support resources. The site supports Merck's competitive advantage in immunotherapy by educating patients and caregivers, potentially improving treatment adherence and outcomes. The presence of a dedicated healthcare professional site indicates a segmented approach to stakeholder engagement. The site integrates with Merck's broader digital ecosystem, linking to corporate and regulatory resources. Growth indicators include comprehensive content updates and multimedia integration. The partnership ecosystem includes regulatory bodies like the FDA and technology providers such as Brightcove and Google. Strategic observations highlight the importance of digital patient support in pharmaceutical marketing and compliance with healthcare regulations.

Security posture

The website demonstrates a mature security posture with HTTPS enforced and multiple security headers implemented, including HSTS, CSP, and X-Frame-Options. No exposed sensitive data or vulnerable libraries were detected in the analysis. The site lacks a publicly visible dedicated security policy or incident response contact, which could be improved to enhance transparency and trust. No vulnerability disclosure or security.txt file was found, representing an opportunity for better security communication. Privacy compliance is strong, with clear privacy and cookie policies and consent mechanisms in place, aligning with GDPR requirements. Overall, the site balances user experience with security best practices, though formal security governance disclosures are limited.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and compliance.
  2. Provide explicit incident response contact information to facilitate vulnerability reporting.
  3. Implement and publish a vulnerability disclosure policy or security.txt file.
  4. Enhance transparency around data retention and user privacy practices.
  5. Continue monitoring and updating third-party libraries to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Merck
Description
KEYTRUDA is an immunotherapy that works with your immune system to help fight certain cancers. It treats 18 types of cancer including early-stage and advanced cancers such as non–small cell lung cancer (NSCLC).
Key services
Cancer treatment information, Patient resources and support, Medication guides and prescribing information
Content quality
excellent
Branding
consistent

Technology

Stack
React, Next.js, Brightcove Video Player, Google Tag Manager, jQuery
Frameworks
Next.js
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
90/100
Good practices seen
  • HTTPS enforced
  • Security headers present
  • No exposed sensitive data detected
  • Secure forms with no visible vulnerabilities

Analytics and tracking

Services
Google Analytics (via Google Tag Manager)
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is comprehensive and medically accurate for KEYTRUDA drug.
  3. Strong branding consistent with Merck pharmaceutical company.
  4. No suspicious or malicious links detected.
  5. Good privacy and cookie policy presence with consent mechanism.
  6. No direct contact emails found; phone support number provided.
  7. No explicit security policy or incident response page found.
  8. Modern tech stack with React and Next.js used.
  9. Good SEO and accessibility features implemented.
  10. No adult or NSFW content detected.
Technical notes

Notes

The site is built on a modern React and Next.js framework, enabling server-side rendering and improved performance. It integrates multimedia content via Brightcove and uses Google Tag Manager for analytics and marketing tags. The presence of jQuery indicates some legacy or third-party components. The site is mobile-optimized with responsive design and accessibility features such as skip links. SEO is supported by meta tags, canonical links, and structured data in JSON-LD format describing the drug and medical webpage. Performance is moderate, with multiple CSS and JS chunks loaded asynchronously. Hosting provider details are not explicit but likely enterprise-grade given Merck's scale. Technical risks are minimal, though continuous performance optimization and security patching are recommended.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with keytruda.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review keytruda.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.